Business Context and Reporting Period
This Form 8-K Current Report was filed by MRI Interventions, Inc. (not Clearpoint Neuro, Inc.) on April 4, 2016. The report details the completion of a note restructuring transaction with Brainlab AG, originally disclosed on March 22, 2016. The transaction involves the modification of debt terms, issuance of equity securities, and entry into a technology license agreement.
Key Financial Metrics and Transaction Details
- Interest Payment: The Company paid $739,323.46 in accrued and unpaid interest on the previous secured note.
- Debt Restructuring: A new secured note ("New Note") was issued with a principal amount of $2,000,000, reduced from the previous principal. The maturity date was extended to December 31, 2018, and interest is now payable quarterly in arrears.
- Debt Cancellation via License: $1,000,000 of the old principal was cancelled in exchange for a patent and technology license agreement for the development of software relating to the SmartFrame device.
- Debt Cancellation via Equity: $1,289,444.44 of the old principal was cancelled in exchange for the issuance of 3,972,410 units.
- Equity Issuance: Each unit consists of one share of common stock, warrants to purchase 0.40 shares (Series A), and warrants to purchase 0.30 shares (Series B).
Material Changes Versus Prior Period
The filing represents a material change in the Company's capital structure and debt obligations. The total principal obligation to Brainlab was significantly reduced through a combination of cash payment, equity issuance, and technology licensing. The maturity of the remaining debt was extended by several years compared to the original note terms.
Guidance, Outlook, and Risks
The filing does not provide forward-looking financial guidance or management commentary regarding future revenue or profit. The primary risk disclosed relates to the unregistered sale of equity securities, which relied on exemptions under Section 4(a)(2) and Regulation S of the Securities Act of 1933. The Company entered into a Registration Rights Agreement to facilitate the future resale of the issued shares and warrant-exercisable shares.
Investor Verification Checklist
- Verify the total reduction in principal debt ($2,289,444.44) and the remaining obligation ($2,000,000).
- Confirm the terms of the Patent and Technology License Agreement regarding the SmartFrame device development.
- Review the valuation and exercise terms of the Series A and Series B warrants issued to Brainlab.
- Check the status of the Registration Rights Agreement and the filing of the registration statement for the resale of shares.
- Note that the filing text does not provide current revenue, profit, or cash flow figures for the reporting period.